Blockade of IL-23: What is in the Pipeline?

被引：63
作者：
Parigi, Tommaso Lorenzo [1 ,2 ]
Iacucci, Marietta [1 ]
Ghosh, Subrata [3 ]
机构：
[1] Univ Hosp NHS Fdn Trust & Univ Birmingham, Inst Immunol & Immunotherapy NIHR Birmingham Biom, Birmingham, W Midlands, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Univ Coll Cork, APC Microbiome Ireland Ctr, Coll Med & Hlth, Cork, Ireland
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷 / SUPPL 2期
关键词：
Interleukin; 23; interleukin; 12; Crohn's disease; ulcerative colitis; anti-IL23 monoclonal antibodies; SEVERE CROHNS-DISEASE; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; INDUCTION THERAPY; DOUBLE-BLIND; USTEKINUMAB; MODERATE; SAFETY; RISANKIZUMAB;
D O I：
10.1093/ecco-jcc/jjab185
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis MCI, promoting a Th17 cell-related immune response. The combined blockade of IL-23 and 2 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.
引用
收藏
页码：II64 / II72
页数：9
相关论文
共 66 条
[1]  
AbbVie, 2021, A randomized, double-blind, placebocontrolled study to evaluate the safety and ePicacy of pitolisant on excessive daytime sleepiness and other non-muscular symptoms in patients with myotonic dystrophy type 1, followed by an open-label extension
[2]  
Adedokun O, 2020, AM J GASTROENTEROL, V115, pS437
[3]  
[Anonymous], 2012, Press Releases
[4]  
[Anonymous], PRESS RELEASE
[5]   Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [J].
Bai, Fan ;
Li, Gang Gang ;
Liu, Qingmin ;
Niu, Xinwu ;
Li, Ruilian ;
Ma, Huiqun .
JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
[6]   Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? [J].
Baker, Kenneth F. ;
Isaacs, John D. .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) :175-187
[7]   Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies [J].
Bossuyt, P. ;
Ferrante, M. ;
Baert, F. ;
Danese, S. ;
Feagan, B. G. ;
Loftus, E. V., Jr. ;
Panes, J. ;
Peyrin-Biroulet, L. ;
Ran, Z. ;
Armuzzi, A. ;
D'Haens, G. R. ;
Song, A. ;
Neimark, E. ;
Liao, X. ;
Zhou, Q. ;
Berg, S. ;
Wallace, K. ;
Panaccione, R. .
JOURNAL OF CROHNS & COLITIS, 2021, 15 :S033-S034
[8]  
Cheng X., BIOMARKER PROFILE PT
[9]   Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, in Normal Healthy Volunteers [J].
Cheng, Xiaoli ;
Lee, Tien-Yi ;
Ledet, Grace ;
Zemade, Genet ;
Tovera, James ;
Campbell, Robert ;
Purro, Nobert ;
Annamalai, Thamil ;
Masjedizadeh, Mohammad ;
Liu, David ;
Nawabi, Roya ;
Kanwar, Bittoo .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 :S439-S440
[10]   Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain [J].
Cua, DJ ;
Sherlock, J ;
Chen, Y ;
Murphy, CA ;
Joyce, B ;
Seymour, B ;
Lucian, L ;
To, W ;
Kwan, S ;
Churakova, T ;
Zurawski, S ;
Wiekowski, M ;
Lira, SA ;
Gorman, D ;
Kastelein, RA ;
Sedgwick, JD .
NATURE, 2003, 421 (6924) :744-748
1234567